The Production of Therapeutic Proteins in Plants: Apo AI and Insulin
The Production of Therapeutic Proteins in Plants: Apo AI and Insulin The Production of Therapeutic Proteins in Plants: Apo AI and Insulin
Leading Product CandidatesProduct Indication Stage of DevelopmentPharmaceuticalBiosimilar Insulin(SBS-1000)Apo AI MilanoDiabetesAcute CoronarySyndrome(atherosclerosis)Phase I/II• SBS-1000 demonstrated to bebioequivalent to commerciallyavailable insulinPreclinical• Positive preliminaryregression/remodeling data• Pre-IND meeting held Q3 2009
InsulinPositioned to Meet the Growing Demand• Diabetes is a worldwide crisis• Increasing emphasis on earlier use in Type 2 diabetes• Escalating demand in the Developing World will further outstrip supply
- Page 1 and 2: The Production of Therapeutic Prote
- Page 3 and 4: SemBioSys OverviewLocation: Calgary
- Page 5 and 6: SemBioSys’ TechnologyProof-of-Con
- Page 7 and 8: Field Grown GMO SafflowerPlanting s
- Page 9 and 10: Purification of OilbodiesThe Proces
- Page 11 and 12: Plant Impurity AssaysPhytate (IP 6
- Page 13 and 14: Product Impurity Assays - Fusion Pa
- Page 15: Viral Load/Viral ClearanceRegulator
- Page 19 and 20: Economics of Plant-Produced Insulin
- Page 21 and 22: Insulin - Equivalence DataV8 Protea
- Page 23 and 24: Insulin - Equivalence DataIGF-1 Rec
- Page 25 and 26: Insulin Characterization: Clinical
- Page 27 and 28: Apo AI Milano (SBS-2000)• FTO - S
- Page 29 and 30: Functional Characterization of Puri
- Page 31 and 32: Cholesterol Mobilization in vivoSBS
- Page 33: Non-Pharma ProductsProducts and Com
Insul<strong>in</strong>Positioned to Meet the Grow<strong>in</strong>g Dem<strong>and</strong>• Diabetes is a worldwide crisis• Increas<strong>in</strong>g emphasis on earlier use <strong>in</strong> Type 2 diabetes• Escalat<strong>in</strong>g dem<strong>and</strong> <strong>in</strong> the Develop<strong>in</strong>g World will further outstrip supply
Change language